Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
about
Current vaccine trials in glioblastoma: a reviewT lymphocytes targeting native receptorsAdoptive cell therapy for sarcomaCellular immunotherapy for pediatric solid tumorsExpression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes.Engineered T cells for cancer treatmentT-cell-based therapies for malignancy and infection in childhood.Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersImmunotherapeutic Intervention against Sarcomas.Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation.Adoptive T cell therapy of cancer.Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo.Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma.Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disordersAdvances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated MalignanciesA phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive TumorsEx vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapyTherapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma.Adoptive transfer of virus-specific and tumor-specific T cell immunityCytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.Combining drugs and biologics to treat nasopharyngeal cancer.Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.Immunotherapy for EBV-associated malignancies.Cellular immunotherapy for high-grade glioma.Is adoptive T-cell therapy for solid tumors coming of age?Adoptive immunotherapy of advanced melanoma.Gene-modified cells for stem cell transplantation and cancer therapy.Current status of engineered T-cell therapy for synovial sarcoma.Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine.A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factorEBV-related lymphomas: new approaches to treatment.Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).
P2860
Q26828965-89CECBD9-177E-4DBF-8046-6F937850DF12Q26853345-FF75738D-88AF-4778-906D-E5402E1D1758Q27009541-89CD8CC3-3844-46B3-A7D9-F615AEF0B7E2Q27014912-D6687026-E158-43B2-A7F5-DC21229E4E63Q30931726-4294C835-8174-4D58-84BF-AC7ADFE4162EQ33578792-0243C41B-1D60-420D-B560-1267ECF628BCQ33750862-2B256286-ABB3-4E1C-B939-FE5C38826E5CQ34039992-26FD6E58-B42A-4B4B-9024-DE512D11CFA0Q34166602-25549B65-88DE-4BE9-89DF-B79FF3346374Q34196481-57409113-7C23-43FB-A5CF-CA11A198BC38Q34242449-C9620D3B-96E9-4FCB-865F-59D475836244Q34707183-B8FC1F50-D2DE-491F-9DE6-F0B27D0FBCE3Q34771143-949B65EB-72A3-4CF6-836F-02686A5E5E99Q34977470-6C1B3691-7467-434C-A35A-0BAF2AF9C63FQ35005421-A08B25E8-1105-453D-8029-6938B1C39EF1Q35483599-268DE574-C3A7-4603-934B-1BB2BB03BF14Q35507358-8046E430-E923-4B2E-8260-60CB7F603DF4Q35570420-FCAC4EBB-13BC-426A-9F29-D6576EC8A181Q35684896-C8269CC1-746F-4A8E-8D21-641223FFEE45Q35738744-18E86304-8343-4211-B910-53CAD5A17985Q35829978-A379D8F2-21A5-4E19-A262-3C11E0E84A8DQ35857642-14F4A21D-986E-4D8F-B8B7-0F5F19BCEA60Q36807231-28ACD3E8-8970-4F3C-9714-67135932B6E4Q37183682-29D41355-C624-411F-87D4-C01C11765990Q37195079-DFD4C608-BC6C-4B6E-8DF7-6B60F66AFB85Q37287275-7789805A-A134-4C7E-B8D9-1BB053875E9AQ37414729-F3490FED-D94D-4461-B3B8-2184CD55C9ACQ37690437-952E38A5-B5BF-4167-9AD2-5AE45D59D00FQ37690461-3669BC41-CAD5-4329-BAB1-BBA4F3792C85Q37809463-4A3EED33-F208-4C66-B423-945D9A0B2EC5Q37845178-08C52F41-8A1E-4B73-9B77-565492D8D288Q37851972-EE176F82-95B0-48B7-B407-1314F91DF15FQ37909004-EFC0F1AF-73AF-4D4C-9E4F-350C7C2B0444Q38032141-836DA033-7ED3-4827-9904-988E81250529Q38230157-BDB57EE5-70A6-4B14-8982-679E1D7BF6DEQ38916522-63DAA28F-5FB5-4F1B-A0B7-28F461C524DFQ39044990-D9A1A73F-40EB-4ABF-93F6-4805729A3A48Q39381467-194B5D06-E8EB-4587-ABD1-9B0830F0AB92Q39441281-F0CED091-124B-4EE5-87E2-572F80191879Q39707175-F8FF9536-9371-41DC-B372-856B476A7B34
P2860
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enhancing the in vivo expansio ...... al antibodies in NPC patients.
@en
Enhancing the in vivo expansio ...... al antibodies in NPC patients.
@nl
type
label
Enhancing the in vivo expansio ...... al antibodies in NPC patients.
@en
Enhancing the in vivo expansio ...... al antibodies in NPC patients.
@nl
prefLabel
Enhancing the in vivo expansio ...... al antibodies in NPC patients.
@en
Enhancing the in vivo expansio ...... al antibodies in NPC patients.
@nl
P2093
P2860
P1433
P1476
Enhancing the in vivo expansio ...... al antibodies in NPC patients.
@en
P2093
Adrian P Gee
Catherine M Bollard
Chrystal U Louis
Claudia Gerken
Cliona M Rooney
Heidi L Weiss
Helen E Heslop
Karin Straathof
M Helen Huls
M Victoria Gresik
P2860
P304
P356
10.1182/BLOOD-2008-05-157222
P407
P577
2008-10-29T00:00:00Z